Supernus Pharmaceuticals Inc (NASDAQ:SUPN) target price raised to $26.00, released a research note earlier today by Zacks Investment Research
- Updated: October 9, 2016
Zacks Investment Research bumped up the target of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to $26.00 reporting a possible upside of 0.09%.
Just yesterday Supernus Pharmaceuticals Inc (NASDAQ:SUPN) traded -0.25% lower at $23.93. Supernus Pharmaceuticals Inc’s 50-day moving average is $23.52 and its 200-day moving average is $20.05. The last stock price is up 18.62% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 503,994 shares of SUPN traded hands, down from an average trading volume of 581,232
Recent Performance Chart
Supernus Pharmaceuticals Inc has one year low of $9.51 and a one year high of $26.84 with a P/E ratio of 48.53 and has a market cap of $0.
General Information About Supernus Pharmaceuticals Inc (NASDAQ:SUPN)
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It develops multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). Its psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. It markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.